(Q39280062)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22972494%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22972494%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22972494%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Nicholas P. Restifo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22972494%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

L Zhang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22972494%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Z Yu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22972494%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

P Muranski

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22972494%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

S A Rosenberg

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22972494%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

R A Morgan

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22972494%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

13 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22972494%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22972494%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22972494%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22972494%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

575-580

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22972494%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/gt.2012.75

13 February 2020

exact match

0 references

cites work

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Development of TGF-beta signalling inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

TGF beta secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Transforming growth factor-beta in T-cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Cloning of a type I TGF-beta receptor and its effect on TGF-beta binding to the type II receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

TGFbeta signalling: a complex web in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

The soluble transforming growth factor-beta receptor: advantages and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Oncolytic adenovirus expressing soluble TGFβ receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Tumor-specific Th17-polarized cells eradicate large established melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Cutting edge: antigen-specific TGF beta-induced regulatory T cells suppress Th17-mediated autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

TRAF6 inhibits Th17 differentiation and TGF-beta-mediated suppression of IL-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Role of SMAD and non-SMAD signals in the development of Th17 and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Adoptive immunotherapy of cancer using CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Tolerance induced by inhaled antigen involves CD4(+) T cells expressing membrane-bound TGF-beta and FOXP3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease

21 January 2018

1 reference

12 December 2020

Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.

1 reference

12 December 2020

Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft.

1 reference

12 December 2020

Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis.

1 reference

12 December 2020

Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines

1 reference

12 December 2020

Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer

1 reference

12 December 2020

Radiosensitivity with Par-4 expression in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.75

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/GT.2012.75

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22972494%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22972494%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

PubMed publication ID

22972494

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22972494%20AND%20SRC:MED&resulttype=core&format=json